曲妥珠单抗联合白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效和安全性  

The efficacy and safety of trastuzumab and albumin - bound paclitaxel in patients with advanced breast cancer

作　　者：朱华云[1] 孙小峰[1] 陈嘉[1] 吴平平[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《徐州医学院学报》2015年第11期752-755,共4页Acta Academiae Medicinae Xuzhou

摘　　要：目的探讨曲妥珠单抗联合白蛋白结合型紫杉醇治疗人表皮生长因子受体2（human epidermal growth factor receptor-2，HER-2）阳性晚期乳腺癌的近期疗效和安全性。方法回顾性分析16例HER-2阳性晚期乳腺癌患者使用曲妥珠单抗联合白蛋白结合型紫杉醇方案二线以上治疗的资料，评估其疗效、不良反应及疾病进展情况。曲妥珠单抗首次给药剂量8mg／kg，静脉滴注90min；后每次剂量6me／kg，静脉滴注60min，每21天给药1次。白蛋白结合型紫杉醇给药剂量为130mg／m2，静脉滴注30min，第1、8天，21天为1个周期。每2个周期评估疗效及不良反应。结果16例患者均可评价疗效，客观缓解率（objective response rate，ORR）37．5％，临床获益率（clinical benefit rate，CBR）达93．8％，中位无疾病进展时间（progression free survival，PFS）为7．3个月。主要不良反应包括血液学毒性、消化道反应、感觉神经病变、肌肉关节痛、发热、脱发等。结论曲妥珠单抗联合白蛋白结合型紫杉醇方案是HER-2阳性晚期乳腺癌二线以上治疗的有效解救方案，且不良反应均可耐受。Objective To evaluate the efficacy and safety of trastuzumab combined with albumin - bound paclitaxel in patients with human epidermal growth factor receptor - 2 （ HER - 2 ） positive advanced breast cancer. Methods Clinical data were collected from sixteen patients with HER - 2 positive advanced breast cancer who were treated with trastuzumab combined with albumin -bound paclitaxel before retrospective analysis. Then, their efficacy, adverse reac- tions and progression of the disease were evaluated. Trastuzumab was administered （ivgtt） at an initial dose of 8 mg/kg within 90 min followed by a maintenance dose of 6 mg/kg within 60 rain, once per 21 days. Albumin - bound paclitaxel was administered （ivgtt） at a dose of 130 mg/m2 over 30 minutes on Days 1 and 8, with 21 day as a cycle. The efficacy and safety were assessed every two cycles. Results All patients were evaluated for clinical efficacy. The objective re- sponse rate （ORR） was 37.5% , the clinical benefit rate was 93.8% and the median progression free survival （PFS） was 7.3 months. The main adverse reactions included hematological toxicity, gastrointestinal reactions, sensory neuropathy, myodynia/arthragia, fever, and alopecia. Conclusions Trastuzumab and albumin -bound paclitaxel based chemotherapy is effective to treat HER- 2 positive advanced breast cancer, with mild adverse reactions.

关 键 词：曲妥珠单抗 白蛋白结合型紫杉醇 乳腺癌 疗效 安全性 

分 类 号：R737.9[医药卫生—肿瘤]